Skip to main content
    N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $165.31
    -2.09 (-1.25%)

    Market Cap: $16.94B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neurocrine Biosciences Inc (NBIX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Neurocrine Biosciences (NBIX) trades at 18.4x trailing earnings and 4.5x sales. Its P/E of 18.4x is below its 5-year median of 24.7x. Its forward P/E is 16.4x. The median P/E across 10 similar companies is 19.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 12.2% higher over the next year. Its free cash flow yield is 6.2%.

    MultipleValue
    P/E (trailing)18.4x
    Forward P/E16.4x
    Price to sales4.5x
    Price to book4.3x
    EV/EBITDA16.9x
    Price to FCF16.2x
    EV/FCF15.6x
    PEG0.3
    FCF yield6.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 47.1% below 8.5x and its P/B is 38.6% below 7.0x.

    MultipleCurrent5-year median10-year median
    P/E18.4x24.7xN/A
    P/S4.5x6.1x8.5x
    P/B4.3x5.4x7.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 21.6x in 2024 to 420.1x in 2018.

    Year endPriceP/EP/SP/B
    2025$141.8322.2x5.0x4.5x
    2024$136.5021.6x5.9x5.4x
    2023$131.7634.5x6.9x6.0x
    2022$119.4434.5x7.8x7.0x
    2021$85.1747.3x7.1x5.9x
    2020$95.8523.3x8.6x8.3x
    2019$107.49325.7x12.7x16.4x
    2018$71.41420.1x14.5x14.2x
    2017$77.59N/A43.6x19.3x
    2016$38.70N/A111.8x10.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NBIX

    What is NBIX's forward P/E ratio?

    Neurocrine Biosciences has a forward P/E ratio of 16.4x.

    Is NBIX stock overvalued?

    GNG's valuation label for NBIX is Undervalued. Its P/E of 18.4x compares with a median of 19.7x across 10 similar companies.

    What is NBIX's price to sales ratio?

    Neurocrine Biosciences has a price to sales ratio of 4.5x.

    What is Neurocrine Biosciences's average P/E ratio over 5 years?

    Neurocrine Biosciences's median P/E over the last 5 years is 24.7x, from 60 month-end values through Oct 2026.

    What is NBIX's PEG ratio?

    Neurocrine Biosciences has a PEG ratio of 0.3.